Xibornol: multiple dose pharmacokinetics and diffusion in lung, tonsillar tissue and laryngeal mucosa.
In ten patients with severe chronic bronchitis and in a further 23 with planned resection of lung, tonsils or larynx, 500 mg doses, single or multiple, of xibornol (6-isobronyl-3, 4-xylenol) were administered for an antibacterial effect. The pharmacokinetics and diffusion of the drug in the tissues were studied. A high diffusion and distribution value of xibornol was observed, with levels in the tissues constantly higher than that in the serum. The concentrations reached within the respiratory tract were adequate for their antibacterial effect.
Scaglione
F
F
Department of Pharmacology, Chemotherapy and Toxicology, University of Milan, Italy.
Trazzi
R
R
Odero
A
A
Sambataro
G
G
Savio
G
G
Ferrara
F
F
Fraschini
F
F
D000284:Administration, Oral; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D001892:Camphanes / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D004058:Diffusion; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007820:Laryngeal Mucosa / Q000378:metabolism*; D007830:Larynx / Q000378:metabolism*; D008168:Lung / Q000378:metabolism*; D008875:Middle Aged; D014066:Palatine Tonsil / Q000378:metabolism*; D013183:Sputum / Q000032:analysis; D014018:Tissue Distribution
D000890:Anti-Infective Agents; D001892:Camphanes; C003773:xibornol